Avillion

Avillion, a CRO focusing on development of late-stage pharmaceutical candidates from Phase 3 to marketing approval, has appointed Ulf Wiinberg Chairman of its Board of Directors.

Before joining Lundbeck, he worked at Wyeth/Lederle for 27 years, most recently as President of Wyeth Europe and Wyeth BioPharma. Wiinberg is also a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturer Association (IFPMA), Pharmaceutical Research and Manufacturers of America (PhRMA).

Avillion partners with pharmaceutical companies to help their drugs gain marketing authorisation in the US and EU.

Avillion was founded in 2012 in London, UK, and is backed by Abingworth, Clarus Ventures and Royalty Pharma. In February this year, it appointed Allison Jeynes-Ellis​, previously of Wyeth, Bristol-Myers Squibb and Novartis, as CEO.